Myriad Genetics inches closer to acquiring Crescendo Bioscience

Myriad Genetics ($MYGN) is inching closer to snatching up molecular diagnostic test maker Crescendo Bioscience. Utah-based Myriad first made its interest known back in 2011, when it invested $25 million into Crescendo with a three-year option to buy the South San Francisco company. Since then, Crescendo has achieved a number of milestones, such as winning Medicare coverage over the summer for its Vectra DA test for rheumatoid arthritis. Myriad said in a regulatory filing that in the wake of Crescendo meeting a "minimum revenue milestone," it has notified executives "of its preliminary, non-binding interest in completing the merger," subject to the necessary due diligence. Regulatory filing

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.